검색어: myopia (영어 - 슬로베니아어)

myopia
kratkovidnost

myopia,
astenopija,

pathological myopia
bolezenska kratkovidnost

myopia, asthenopia,
miopija,

acute myopia and angle-closure glaucoma
akutna miopija in glavkom zaprtega zakotja

papilloedema, reduced visual acuity*, myopia*
papiloedem, zmanjšanje ostrine vida *, miopija *

acute myopia and secondary acute angle-closure glaucoma
akutna kratkovidnost in sekundarni akutni glavkom z zaprtim zakotjem

maximum corrective lenses: hypermetropia + 5/myopia — 8.
najmočnejše korektivne leče: daljnovidnost + 5/kratkovidnost – 8.

- patients with subfoveal choroidal neovascularisation secondary to pathological myopia.
- bolnikov s subfovealno horioidalno neovaskularizacijo zaradi bolezenske kratkovidnosti.

scotoma, scleral discolouration, mydriasis, photophobia, myopia, lacrimation increased
redki skotom, obarvanje beločnice, midriaza, fotofobija, miopija, močnejše solzenje

scotoma, scleral discolouration, eye pain, mydriasis, photophobia, myopia, lacrimation increased
skotom, obarvanje beločnice, bolečine v očeh, midriaza, fotofobija, miopija, močnejše solzenje

undesirable effects reported in patients with pathological myopia were similar to those reported in patients with amd.
pri bolnikih z bolezensko kratkovidnostjo so poročali o podobnih neželenih učinkih kot pri bolnikih s starostno degeneracijo makule.

visudyne has also been studied for two years in 120 patients with subfoveal choroidal neovascularisation caused by pathologic myopia.
zdravilo visudyne so dve leti raziskovali tudi pri 120 bolnikih s subfovealno horoidno neovaskularizacijo, ki jo povzroča bolezenska kratkovidnost.

for choroidal neovascularisation due to pathologic myopia, lucentis was compared with verteporfin pdt in one main study involving 277 patients.
pri horoidalni neovaskularizaciji zaradi bolezenske kratkovidnosti so zdravilo lucentis primerjali s fotodinamično terapijo (pdt) z verteporfinom v eni glavni študiji z 277 bolniki.

visudyne is used for the treatment of predominantly classic cnv in amd patients, and of all types of cnv in pathological myopia patients.
visudyne se uporablja za zdravljenje pretežno klasične cnv pri bolnikih z amd, pa tudi vseh vrst cnv pri bolnikih z bolezensko kratkovidnostjo.

myopic choroidal neovascularisation (myopic cnv) is a frequent cause of vision loss in adults with pathologic myopia.
miopična horoidalna neovaskularizacija (miopična cnv) je pogost vzrok izgube vida pri odraslih s patološko kratkovidnostjo.

visudyne should be administered only by ophthalmologists experienced in the management of patients with age-related macular degeneration or with pathological myopia.
zdravilo visudyne naj aplicirajo samo oftalmologi, ki imajo izkušnje z zdravljenjem bolnikov s starostno degeneracijo makule ali z bolezensko kratkovidnostjo.

eye disorders not known: transient blurred vision, xanthopsia, acute myopia and secondary acute angle-closure glaucoma
očesne bolezni neznana pogostnost: prehodno zamegljen vid, ksantopsija, akutna kratkovidnost in sekundarni akutni glavkom z zaprtim zakotjem

for choroidal neovascularisation caused by pathological myopia, many patients may only need one or two injections during the first year of treatment, while some patients may need more frequent treatment.
pri horoidalni neovaskularizaciji, ki jo povzroča bolezenska kratkovidnost, bo morda mnogo bolnikov v prvem letu zdravljenja potrebovalo samo eno ali dve injekciji, medtem ko bodo drugi potrebovali pogostejše injiciranje.

it develops as a wound healing mechanism consequent to bruch’s membrane ruptures and represents the most vision-threatening event in pathologic myopia.
razvije se kot mehanizem za celjenje ran, ki so posledice ruptur bruchove membrane in najbolj ogrožajo vid pri patološki kratkovidnosti.